

## **Discovery Minerals signs LOI with Neurocyte Inc and Migranade.**

OTC Disclosure & News Service

December 18<sup>th</sup>, 2015--- Los Angeles, CA. Discovery Minerals Ltd. (OTC PINK: DSCR)

Discovery Minerals Ltd has signed a Letter of Intent with Neurocyte Inc to jointly manufacture and market a homeopathic migraine headache therapy called Migranade. Migranade is registered with the FDA and has a national drug code number : 60916-002-02 This patented therapy was developed by Dr Charles Hensley in his research facility in Southern California. Dr Hensley is an energetic and prolific inventor of homeopathic treatments and systems for common human ailments and was responsible for developing "Zicam" in the late 90s, a well known treatment for the common cold, which is still sold from Pharmacy shelves today.

According to figures released by the Migraine Research Foundation, migraine is an extraordinarily common disease that affects 36 million men, women & children in the USA, about 10% of the population.

Approximately 14 million people experience chronic daily headache – when attacks occur at least 15 days per month.

Migraine ranks in the top 20 of the world's disabling diseases.

Only 4% of migraine sufferers who seek medical care consult headache and pain specialists.

Dr Hensley states that his research was motivated by the possibility of finding an effective, low cost naturopathic therapy that could be readily available over the counter.

The BOD of Discovery is very enthusiastic about becoming involved with a product of this nature that has been manufactured in bulk and has already been test marketed on a limited basis.

### About Discovery Minerals LTD.:

Discovery Minerals Ltd., (OTC PINKSHEETS: DSCR.PK) is an acquisition and development company that targets natural resource properties and cutting edge technology opportunities through its subsidiaries. The Board of Directors has determined that these activities be clearly defined and separated within the company. The marketing of Migranade and the further development of Dr Hensley's multiple homeopathic treatments and the delivery systems for these therapies will be the main focus of Discovery's commercial thrust. All previous operations and activities such as precious metals/mining and industrial hemp growing & processing and clean alternative energy technology will be preserved and held in a new corporate structure as a subsidiary. Suitable management recruits are being sought for these pursuits by Discovery at this time. Shareholders will be kept advised of these arrangements in the normal way.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact Person:

Russell Smith At: [info@discoveryholdingscorp.com](mailto:info@discoveryholdingscorp.com)

1-310-961-4654